

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: G. SCHMIDMAIER et al.

Confirmation No.: 8071

Application No.: 09/801,752

Group Art Unit: 1615

Filed: March 9, 2001

Examiner: H. Sheikh

For:

BIOLOGICALLY ACTIVE IMPLANTS

Attorney Docket No.: 8932-148

FOURTH INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Pursuant to applicants' duty of disclosure under 37 C.F.R. § 1.56 and § 1.97(h), enclosed is a substitute Form PTO-1449, entitled "List of References Cited by Applicant, which lists 24 references in reverse chronological order, copies of which are enclosed for the Examiner's convenience. It is respectfully requested that these references be made of record in this application by the Examiner's completion and return of the substitute Form PTO-1449.

As this Information Disclosure Statement is being filed after receipt of the first office action on the merits, but before the mailing date of a final office action or notice of allowance, the fee for this submission pursuant to 37 C.F.R. §1.17(p) is believed to be \$180.00. Please charge this fee and any additionally required fees to Pennie & Edmonds LLP Deposit Account No. 16-1150.

November **6**, 2003 Date

11/07/2003 CNGUYEN 00000090 161150 09801752

180.00 DA

Arthur M. Antonelli For

Rég. No. 51,410

Brian M. Rothery

Reg. No. 35,340

PENNIE & EDMONDS LLP

1667 K Street, N.W. Washington, DC 20006

Respectfully submifted

(202) 496-4400

Enclosures

01 FC:1806

DC1: 358794.1

NOV 0 6 2003

U.S. PATENT DOCUMENTS

NOV 0 6 2003 ATTY DOCKET NO. APPLICATION 8932-148 09/801,75	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) G. SCHMIDMAIER et al. FILING DATE March 9, 2001 1615 U.S. PATENT DOCUMENTS *EXAMINER INITIAL DOCUMENT NUMBER DATE NAME CLASS SUBCLASS	
*EXAMINER INITIAL DOCUMENT NUMBER DATE NAME CLASS SUBCLASS	
*EXAMINER INITIAL DOCUMENT NUMBER DATE NAME CLASS SUBCLASS	CENTED 200
*EXAMINER INITIAL DOCUMENT NUMBER DATE NAME CLASS SUBCLASS	1600/2
5005 500	FILING DATE IF APPROPRIATE
Add 1 - 7 - 7 - 7 - 1	
A02 5,770,255 6/23/1998 Burrell et al. 427 2.1	
A03 5,759,564 6/2/1998 Milder et al. 424 426	
A04 5,108,399 4/28/1992 Eitenmuller et al. 606 77	
A05 4,476,590 10/16/1984 Scales et al. 3 1.91	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSL * Abstrac	
							YES_	NO
	B01	EP 0 792 654 A2	9/3/1997	Europe			*X	
1	B02	WO 89/04674	6/1/1989	PCT				

OTHER REFERENCES	(Including Author	Title Date	Pertinent Pages Ftc)

C01	F. Kandziora et al., "Experimentelle Spondylodese der Schafshalswirbelsäule," Der Chirurg, 2002, 73:1025-1038.
C02	M. Lucke et al., "Gentamicin coating of metallic implants reduces implant-related osteomyelitis in rats," <u>Bone</u> , 32 (2003), pp 521-531.
C03	H. Bail et al., "Systemic application of growth hormone enhances the early healing phase of osteochondral defects-a preliminary study in micropigs," <u>Bone</u> , 32 (2003), pp 457-467.
. C04	G. Schmidmaier et al., "Bone Morphogenetic Protein-2 Coating of Titanium Implants Increases Biomechanical Strength and Accelerates Bone Remodeling in Fracture Treatment: A Biomechanical and Histological Study in Rats," Bone, Vol. 30, No. 6, June 2002:816-822.
C05	B. Wildemann et al., "Cell Proliferation and Differentiation During Fracture Healing Are Influenced by Locally Applied IGF-1 and TGF-β1: Comparison of Two Proliferation Markers, PCNA and BrdU," 2003 Wiley Periodicals, Inc., pp 150-156.
C06	T. Pufe et al., "Quantitative measurement of the splice variants 120 and 164 of the angiogenic peptide vascular endothelial growth factor iin the time flow of fracture healing: a study in the rat," Cell Tissue Res, (2002) 309:387-392.
C07	F. Kandziora et al., "IGF-I and TGF-β1 Application by a Poly-(D,L-Lactide)-Coated Cage Promotes Intervertebral Bone Matrix Formation in the Sheep Cervical Spine," <u>SPINE</u> , Volume 27, Numer 16, pp 1710-1723, 2002.
C08	F. Kandziora et al., "Bone morphogenetic protein-2 application by a poly(D,L-lactide)-coated interbody cage: in vivo results of a new carrier for growth factors," J Neurosurg (Spine 1), 97:40-48, 2002.
C09	G. Schmidmaier et al., "Improvement of Fracture Healing by Systemic Administration of Growth Hormone and Local Application of Insulin-like Growth Factor-1 and Transforming Growth Factor-β1," <u>Bone</u> , Vol. 31, No. 1, July 2002:165-172.
C10	F. Kandziora et al., "Bone morphogenetic protein-2 application by a poly(D,L-lactide)-coated interbody cage: in vivo

	91	
	4	results of a new carrier for growth factors," J Neurosurg (Spine 1) 97:40-48, 2002.
A TRADEM	C11	G. Schmidmaier et al., "IGF-1 and TGF-Beta 1 Incorporated in a Poly(D,L-Lactide) Implant Coating Stimulates Osteoblast Differentiation and Collagen-1 Production but Reduces Osteoblast Proliferation in Cell Culture," 2003 Wiley Periodicals, Inc., pp 157-162.
•	C12	M. Raschke et al., "Insulin-like Growth Factor-1 and Transforming Growth Factor-β1 Accelerates Osteotomy Healing Using Polyactide-coated Implants as a Delivery System: A Biomechanical and Histological Study in Minipigs," Bone, Vol. 30, No. 1, January 2002:144-151.
	C13	M. Raschke et al., "Homologous Growth Hormone Accelerates Healing of Segmental Bone Defects," <u>Bone</u> , Vol. 29, No. 4, October 2001:368-373.
	C14	G. Schmidmaier et al., "A New Electrochemically Graded Hydroxyapatite Coating for Osteosynthetic Implants Promotes Implant Osteointegration in a Rat Model," 2002 John Wiley & Sons, Inc., pp 168-172.
	C15	F. Kandziora et al., "Comparison of BMP-2 and combined IGF-1/TGF-β1 application in a sheep cervical spine fusion model," Eur Spine J, (2002), 11:482-493.
	C16	G. Schmidmaier et al., "Local Application of Growth Factors (Insulin-Like Growth Factor-1 and Transforming Growth Factor-β1) From a Biodegradable Poly(D,L-lactide) Coating of Osteosynthetic Implants Accelerates Fracture Healing in Rats," <u>Bone</u> , Vol. 28, No. 4, April 2001:341-350.
	C17	G. Schmiddmaier et al., "Biodegradable Poly(D,L-Lactide) Coating of Implants for Continuous Release of Growth Factors," 2001 John Wiley & Sons, Inc., pp 449-455.

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

NOV 1 4 2003

TECH CENTER 1600/2900